Study: Most accelerated approval indications don’t add high therapeutic value

Less than half of the new drug indications approved through the accelerated approval pathway in the United States and the conditional marketing authorization pathway in Europe offered “high added therapeutic value,” according to an analysis of approvals from 2007 through 2021. A lower proportion of cancer indications were rated as having high therapeutic value, compared with non-cancer indications.